The estimated Net Worth of Tsontcho Ianchulev is at least $2.71 Million dollars as of 1 May 2023. Tsontcho Ianchulev owns over 90,000 units of Eyenovia Inc stock worth over $185,478 and over the last 7 years he sold EYEN stock worth over $1,275,000. In addition, he makes $1,247,140 as Chief Executive Officer, Director, and Chief Medical Officer at Eyenovia Inc.
Sign up
Tsontcho Ianchulev EYEN stock SEC Form 4 insiders trading
Tsontcho has made over 11 trades of the Eyenovia Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 90,000 units of EYEN stock worth $495,000 on 1 May 2023.
The largest trade he's ever made was exercising 313,686 units of Eyenovia Inc stock on 2 January 2019 worth over $483,076. On average, Tsontcho trades about 47,297 units every 96 days since 2018. As of 1 May 2023 he still owns at least 331,211 units of Eyenovia Inc stock.
You can see the complete history of Tsontcho Ianchulev stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Tsontcho Ianchulev biography
Dr. Tsontcho Ianchulev M.D. serves as Chief Executive Officer, Director, Chief Medical Officer of the Company. From 2009 to 2016, he was the chief medical officer and the head of technology and business development for Transcend Medical, Inc. (acquired by Novartis International AG/Alcon, Inc. (NYSE: NVS)). Prior to that, while at Genentech, Inc. (NYSE: DNA, before going private in 2009), Dr. Ianchulev headed the ophthalmology research group and directed the development and the FDA approval of Lucentis. Dr. Ianchulev currently serves as a director of the ASCRS Foundation, and is a member of the Board of Directors of Iantrek, Inc. and AEye, Inc. He was formerly chairman of the board of directors of ianTECH from 2014 until its acquisition by Carl Zeiss Meditec AG (ETR: AFX) in 2019. Dr. Ianchulev received his B.S. from the University of Rochester. He received both his M.D. and an M.P.H. from Harvard University and completed his specialty training at the Doheny Eye Institute. Currently, Dr. Ianchulev serves as a professor in the New York Eye and Ear Infirmary of Mount Sinai.
What is the salary of Tsontcho Ianchulev?
As the Chief Executive Officer, Director, and Chief Medical Officer of Eyenovia Inc, the total compensation of Tsontcho Ianchulev at Eyenovia Inc is $1,247,140. There are no executives at Eyenovia Inc getting paid more.
What's Tsontcho Ianchulev's mailing address?
Tsontcho's mailing address filed with the SEC is C/O EYENOVIA, INC., 295 MADISON AVENUE, SUITE 2400, NEW YORK, NY, 10017.
Insiders trading at Eyenovia Inc
Over the last 7 years, insiders at Eyenovia Inc have traded over $1,275,000 worth of Eyenovia Inc stock and bought 6,072,235 units worth $17,599,075 . The most active insiders traders include Ernest Mario, Stuart M. Grant, and Fredric N Eshelman. On average, Eyenovia Inc executives and independent directors trade stock every 31 days with the average trade being worth of $49,678. The most recent stock trade was executed by Michael M Rowe on 28 August 2024, trading 27,071 units of EYEN stock currently worth $14,077.
What does Eyenovia Inc do?
eyenovia, inc. (nasdaq: eyen) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, presbyopia, mydriasis and other eye diseases.
What does Eyenovia Inc's logo look like?
Complete history of Tsontcho Ianchulev stock trades at Eyenovia Inc
Eyenovia Inc executives and stock owners
Eyenovia Inc executives and other stock owners filed with the SEC include:
-
Tsontcho Ianchulev,
Chief Executive Officer, Director, Chief Medical Officer -
Dr. Tsontcho Ianchulev M.P.H., M.D., MPH,
CEO, Pres, Chief Medical Officer & Director -
John Gandolfo,
Chief Financial Officer, Secretary -
John P. Gandolfo CPA,
CFO & Sec. -
Michael Rowe,
Vice President - Commercial -
Jennifer Clasby,
Vice President - Clinical Operations -
Michael M. Rowe,
Chief Operating Officer -
Fredric Eshelman,
Independent Chairman of the Board -
Tram Bui,
IR Contact Officer -
Anthony Sun,
Independent Director -
Charles Mather,
Independent Director -
Ernest Mario,
Independent Director -
Kenneth Lee,
Independent Director -
Curt Labelle,
Director -
Luke Clauson,
Vice President - Research &Development and Manufacturing -
Norbert Lowe,
VP of Sales & Marketing -
Alexander Lobo,
Investor Contact -
Andrew D. Jones,
Chief Financial Officer -
Julia A Haller,
-
Bren Kern,
Chief Operating Officer -
Pharmaceutical Co., Ltd. Senju,
10% owner -
Shuhei Yoshida,
Director -
Stuart M. Grant,
-
Stephen Keith Benjamin,
-
Rachel Jacobson,
Director -
Ellen R Strahlman,
Director -
Michael S Geltzeiler,
Director -
Ram Palanki,
Director